Literature DB >> 21318582

Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis.

Shaheeda Ahmed1, C Michael Gibson, Christopher P Cannon, Sabina A Murphy, Marc S Sabatine.   

Abstract

Reduced glomerular filtration rate (GFR) is associated with adverse outcomes in patients with cardiovascular disease. We explored the relationship between GFR and angiographic and clinical outcomes in ST-segment elevation myocardial infarction (STEMI) patients receiving pharamacologic reperfusion, with or without clopidogrel. Data were available to estimate GFR in 3,252 STEMI patients undergoing fibrinolysis, randomized to clopidogrel versus placebo in the CLARITY-TIMI 28 trial. Patients with a creatinine > 2.5 mg/dl were excluded from the trial. We compared outcomes between patients with no, mild or moderate reductions in baseline estimated GFR (ml/min/1.73 m²) of ≥ 90, 60-89, and <60, respectively. Compared to patients with no (n = 841) or mildly reduced GFR (n = 1897), those with moderately reduced GFR (n = 514) were older, more often female, and were more likely to have diabetes and hypertension (P ≤ 0.001 for all). The risk of the primary endpoint (an occluded infarct-related artery on angiography or death/myocardial infarction by day 8), 30 day cardiovascular events (death, myocardial infarction, or urgent revascularization for recurrent ischemia) and 30 day Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding increased as GFR declined (P for trend 0.003, <0.0001, and 0.0008 respectively). The adjusted risk of 30 day ischemic complications remained higher in patients with moderately reduced versus normal GFR (OR 1.5, 95% CI 1.0-2.1, P = 0.04). Treatment with clopidogrel tended to yield greater benefit in patients with normal or mildly reduced GFR versus in patients with moderately reduced GFR. In conclusion, STEMI patients with reduced GFR treated with medical reperfusion, including dual antiplatelet therapy, have higher rates of adverse clinical outcome. Further research on optimal STEMI therapy in this high-risk group is warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21318582     DOI: 10.1007/s11239-011-0566-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  21 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors.

Authors:  Rosario V Freeman; Rajendra H Mehta; Wisam Al Badr; Jeanna V Cooper; Eva Kline-Rogers; Kim A Eagle
Journal:  J Am Coll Cardiol       Date:  2003-03-05       Impact factor: 24.094

Review 3.  Platelet dysfunction in renal failure.

Authors:  Paola Boccardo; Giuseppe Remuzzi; Miriam Galbusera
Journal:  Semin Thromb Hemost       Date:  2004-10       Impact factor: 4.180

4.  National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors:  Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

5.  Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006.

Authors:  C Michael Gibson; Yuri B Pride; Paul D Frederick; Charles V Pollack; John G Canto; Alan J Tiefenbrunn; W Douglas Weaver; Costas T Lambrew; William J French; Eric D Peterson; William J Rogers
Journal:  Am Heart J       Date:  2008-11-01       Impact factor: 4.749

6.  Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes.

Authors:  Jassim Al Suwaidi; Donal N Reddan; Kathryn Williams; Karen S Pieper; Robert A Harrington; Robert M Califf; Christopher B Granger; E Magnus Ohman; David R Holmes
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

Review 7.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

8.  Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.

Authors:  Dominick J Angiolillo; Esther Bernardo; Manel Sabaté; Pilar Jimenez-Quevedo; Marco A Costa; Jorge Palazuelos; Rosana Hernández-Antolin; Raul Moreno; Javier Escaned; Fernando Alfonso; Camino Bañuelos; Luis A Guzman; Theodore A Bass; Carlos Macaya; Antonio Fernandez-Ortiz
Journal:  J Am Coll Cardiol       Date:  2007-10-01       Impact factor: 24.094

9.  Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease.

Authors:  M P Gawaz; G Dobos; M Späth; P Schollmeyer; H J Gurland; S K Mujais
Journal:  J Am Soc Nephrol       Date:  1994-07       Impact factor: 10.121

10.  Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries.

Authors:  Petr Widimsky; William Wijns; Jean Fajadet; Mark de Belder; Jiri Knot; Lars Aaberge; George Andrikopoulos; Jose Antonio Baz; Amadeo Betriu; Marc Claeys; Nicholas Danchin; Slaveyko Djambazov; Paul Erne; Juha Hartikainen; Kurt Huber; Petr Kala; Milka Klinceva; Steen Dalby Kristensen; Peter Ludman; Josephina Mauri Ferre; Bela Merkely; Davor Milicic; Joao Morais; Marko Noc; Grzegorz Opolski; Miodrag Ostojic; Dragana Radovanovic; Stefano De Servi; Ulf Stenestrand; Martin Studencan; Marco Tubaro; Zorana Vasiljevic; Franz Weidinger; Adam Witkowski; Uwe Zeymer
Journal:  Eur Heart J       Date:  2009-11-19       Impact factor: 29.983

View more
  2 in total

Review 1.  Cardiovascular Pharmacogenomics--Implications for Patients With CKD.

Authors:  Larisa H Cavallari; Darius L Mason
Journal:  Adv Chronic Kidney Dis       Date:  2016-03       Impact factor: 3.620

2.  Temporal trends in treatment strategies and clinical outcomes among patients with advanced chronic kidney disease and ST-elevation myocardial infarctions: results from the Bremen STEMI registry.

Authors:  Johannes Schmucker; Andreas Fach; Rico Osteresch; Luis Alberto Mata Marin; Tina Retzlaff; Stephan Rühle; Daniela Garstka; Uwe Kuhlmann; Ingo Eitel; Rainer Hambrecht; Harm Wienbergen
Journal:  BMC Cardiovasc Disord       Date:  2022-04-01       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.